Switzerland · Delayed Price · Currency is CHF Clariant AG Earnings Call Transcripts
Fiscal Year 2025
-
Delivered flat sales and improved EBITDA margin in 2025 amid challenging markets, with strong cash conversion and progress on cost savings. Outlook for 2026 is cautious, with flat sales and further margin improvement targeted, supported by ongoing restructuring and disciplined capital allocation.
-
Q3 2025 saw EBITDA growth and margin improvement despite lower sales, driven by cost savings and performance programs. Guidance for 2025 remains at the low end of sales growth and 17%-18% EBITDA margin, with continued focus on cash conversion and structural cost actions.
-
Q2 2025 saw strong profitability with EBITDA margin before exceptionals up to 17.5% and robust cost savings, despite flat sales in local currency and ongoing market headwinds. Guidance for 2025 was revised to 1–3% sales growth, with profitability targets maintained.
-
Q1 2025 saw 1% local currency sales growth and a 3% EBITDA increase, with margin improvement driven by cost savings and strong Lucas Meyer Cosmetics performance. Guidance remains cautious amid trade tensions, with most restructuring charges front-loaded in H1.
Fiscal Year 2024
-
2024 results met guidance with CHF 4.152 billion sales and 15.8% EBITDA margin, despite a challenging macro environment. 2025 outlook targets 3%-5% sales growth, 17%-18% EBITDA margin before exceptionals, and continued cost savings, with strong performance in Care Chemicals and Adsorbents & Additives.
-
A focused specialty chemicals company targets 4–6% annual sales growth and 19–21% EBITDA margin by 2027, driven by innovation, sustainability, and regional expansion. Major investments in digitalization, AI, and sustainable products underpin growth, with strong positions in Care Chemicals, Catalysts, and Additives.
-
Q3 2024 saw a 1% local currency sales decline and 13% lower EBITDA, with cost savings offsetting weak catalyst volumes. 2024 guidance is for a low single-digit sales decline and 16% EBITDA margin, with medium-term targets reaffirmed.
-
Q2 2024 saw a 3% organic sales decline, but underlying EBITDA margin improved by over 500 bps, driven by growth in Care Chemicals and Adsorbents & Additives. Full-year EBITDA margin guidance was raised to 16%, with cost savings and integration of Lucas Meyer Cosmetics progressing well.